Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Income from Continuing Operations data on record, last reported at 81957000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 321.82% year-over-year to 81957000.0; the TTM value through Dec 2025 reached 32138000.0, changed N/A, while the annual FY2025 figure was 68088000.0, 75.85% up from the prior year.
  • Income from Continuing Operations reached 81957000.0 in Q4 2025 per CAI's latest filing, up from 24325000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 81957000.0 in Q4 2025 and bottomed at 80685000.0 in Q2 2024.